| Document Date: 2015-01-27 14:49:56
Open Document File Size: 168,86 KBShare Result on Facebook
City Osaka / London / / Company ViiV Healthcare Ltd. / Shionogi & Co. Ltd. / Corporate Communications Shionogi & Co. Ltd. / / Country Japan / United States / / Event FDA Phase / / / IndustryTerm treatment of HIV / foreign healthcare reforms / with respect to product / / MedicalCondition HIV infection / HIV / / Organization European Union / United States Food and Drug Administration / European Commission / / Person Isao Teshirogi / Dominique Limet / / / Position President & CEO / Chief Executive Officer / / Product abacavir / lamivudine / Tivicay® / /
SocialTag |
ViiV Healthcare Receives EU marketing authorization for Triumeq®, a Single-pill Regimen Containing the Integrase Inhibitor “Dolutegravir” Osaka, Japan, September 4, Shionogi & Co., Ltd. (Head Office: Osaka; P